EUVIMEDEUVIMED entdecken
Open Access

Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction

Jordan J Wright iD, Douglas B Johnson iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgac689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Jordan J Wright und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Hauptthemen laut MEDLINE: Thyroid Diseases, Neoplasms, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICI) are cancer therapies that are approved for use in at least 19 different cancers. They function by stimulating immune cell responses against cancer, and their toxicities comprise a host of autoinflammatory syndromes that may impact any organ system. Endocrine toxicities occur in as high as 25% to 50% of ICI recipients, depending on the treatment regimen used. These toxicities vary in severity from mild, asymptomatic cases of subclinical hypothyroidism to severe, fatal cases of adrenal crisis, thyroid dysfunction, or diabetic ketoacidosis. Thus, timely recognition and treatment is critical. Herein, we present clinical cases of ICI-induced thyroid dysfunction, hypophysitis, and insulin-dependent diabetes mellitus. We use these cases to discuss the screening, diagnosis, and management of ICI-associated endocrine dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid DiseasesNeoplasmsDiabetes Mellitus, Type 1HumansImmune Checkpoint InhibitorsImmunotherapy

Stichwörter der Autor:innen

diabetesendocrineimmune checkpoint inhibitorimmunotherapypituitarythyroid

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

ORCID-Profile: Jordan J Wright, Douglas B Johnson

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • NIH

Zitieren

APA

Wright, J. J., & Johnson, D. B. (2023). Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac689

Vancouver

Wright JJ, Johnson DB. Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac689

BibTeX
@article{Wright2023,
  author = {Wright, Jordan J and Johnson, Douglas B},
  title = {Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgac689}
}
Kostenlos starten →